

June 15, 2007

Press Release

Ajinomoto Co., Inc.

Eisai Co., Ltd.

A ONCE-WEEKLY ANTIOSTEOPOROTIC AGENT "ACTONEL"®

2. In large clinical trials with the primary endpoint of the reduction of frequency of hip fractures, this agent showed statistically significant difference as compared to placebo.

Ajinomoto and Eisai are committed to treatment of osteoporosis patients in Japan and increasing benefits to them through marketing “Actonel[®] tablets”.

Reference

Product outline of “Actonel[®] 17.5 mg tablets”

Brand Name

“Actonel[®] 17.5 mg tablets”

Generic Name

Risedronate sodium hydrate

Indication

Osteoporosis

